Your browser doesn't support javascript.
loading
Comparison of cerebral safety after atrial fibrillation using pulsed field and thermal ablation: Results of the neurological assessment subgroup in the ADVENT trial.
Patel, Chinmay; Gerstenfeld, Edward P; Gupta, Sanjaya K; Winterfield, Jeffrey; Woods, Christopher; Natale, Andrea; Schneider, Christopher W; Achyutha, Anitha B; Holland, Scott K; Richards, Elizabeth; Albrecht, Elizabeth M; Lehmann, John W; Mansour, Moussa; Reddy, Vivek Y.
Afiliação
  • Patel C; UPMC Pinnacle, Harrisburg, Pennsylvania. Electronic address: patelcp@upmc.edu.
  • Gerstenfeld EP; University of California San Francisco, San Francisco, California.
  • Gupta SK; Saint Luke's Mid-America Heart Institute, Kansas City, Missouri.
  • Winterfield J; Medical University of South Carolina, Charleston, South Carolina.
  • Woods C; Sutter California Pacific Medical Center, San Francisco, California.
  • Natale A; Texas Cardiac Arrhythmia Institute, Houston, Texas.
  • Schneider CW; Boston Scientific Corporation, St Paul, Minnesota.
  • Achyutha AB; Boston Scientific Corporation, St Paul, Minnesota.
  • Holland SK; Medpace Core Laboratories, Cincinnati, Ohio.
  • Richards E; Boston Scientific Corporation, St Paul, Minnesota.
  • Albrecht EM; Boston Scientific Corporation, St Paul, Minnesota.
  • Lehmann JW; Lehmann Consulting, Naples, Florida.
  • Mansour M; Massachusetts General Hospital, Boston, Massachusetts.
  • Reddy VY; Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Heart Rhythm ; 2024 May 31.
Article em En | MEDLINE | ID: mdl-38823667
ABSTRACT

BACKGROUND:

Atrial fibrillation (AF) ablation carries the risk of silent cerebral event (SCE) and silent cerebral lesion (SCL). Although "silent," these may have long-term clinical implications and are challenging to study as postprocedural magnetic resonance imaging (MRI) is not standard of care.

OBJECTIVE:

The neurological assessment subgroup (NAS) of ADVENT compared cerebral effects of pulsed field ablation (PFA) with standard-of-care thermal ablation.

METHODS:

The NAS included consecutive randomized PFA and thermal ablation patients who received postprocedural brain MRI 12-48 hours after ablation. Patients with apparent SCE or SCL findings underwent a modified Rankin scale assessment. MRI images were subsequently reviewed by a blinded brain imaging core laboratory.

RESULTS:

In total, 77 patients with paroxysmal AF were enrolled at 6 centers; 71 had analyzable scans (34 PFA; 37 thermal ablation). Through individual center review, 6 PFA and 4 thermal scans were identified as SCE/SCL positive, of which 3 PFA and 0 thermal SCE/SCL findings were confirmed by a blinded core laboratory. MRI findings revealed 1 patient with 2- to 4-mm SCEs, 1 patient with a 3-mm SCE, and 1 patient with 2 SCLs (5.5 mm and 11 mm). All modified Rankin scale and National Institutes of Health Stroke Scale scores were 0 before discharge and at 90-day follow-up. There were only 2 neurological safety events (1 transient ischemic attack [PFA] and 1 stroke [thermal ablation]) in the ADVENT study, neither of which was part of the NAS.

CONCLUSION:

The ADVENT trial provides the first prospective, randomized data on the cerebral impact of PFA and thermal ablation of AF. Incidence of SCE/SCL after ablation in the NAS was low.
Palavras-chave

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Idioma: En Revista: Heart Rhythm Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Idioma: En Revista: Heart Rhythm Ano de publicação: 2024 Tipo de documento: Article